Arvinas (NASDAQ:ARVN) focuses on developing protein degradation therapeutics aimed at fighting cancer and other diseases. This innovative approach seeks to use the body's own machinery to degrade and remove disease-causing proteins. Their projects revolve around leveraging their proprietary PROTAC® Discovery Engine to advance a pipeline of novel drug candidates that have the potential to bring new treatments to patients in need. Arvinas' objectives center on progressing these drug candidates through clinical trials, with a strong emphasis on those targeting prostate and breast cancer. By harnessing the power of protein degradation, Arvinas aims to create a new class of drugs that could provide significant benefits over traditional therapies.